Quantum Pharmaceuticals
Quantum Pharmaceuticals is a technology based drug discovery company. We develop a unique computational drug discovery platform (QUANTUM), provide drug discovery services, and pursue our own in-house drug discovery projects searching for novel compounds with anti-bacterial, anti-viral and anti-cancer efficacy.
Quantum@linkedin.com
Contacts: office@q-pharm.com or comment any post on the site. You are welcome!Subscription Options:
Categories
- absorbtion (3)
- active transport (2)
- ADME (4)
- albumin (1)
- antibiotics (1)
- antiviral (4)
- bioavailability (3)
- cancer (3)
- cardiotoxicity (1)
- collaboration (13)
- compound libraries (1)
- COPD (1)
- docking (12)
- drug design (4)
- drug discovery platform (1)
- druglikeness (4)
- false postive (3)
- flue (1)
- Generalized Born (15)
- GPCR (1)
- HERG (6)
- HIV (2)
- HIV-1 integrase (1)
- HSV (1)
- human neutrophil elastase (1)
- IC50 (18)
- inflammation (3)
- kinase (1)
- LD50 (2)
- logP (1)
- mechanism of action exploration (2)
- MRDD (3)
- new therapeutic uses (1)
- oncology (4)
- openbabel (3)
- PDK1 (1)
- polar liquid (16)
- publications (10)
- q-Mol (1)
- QSAR (1)
- Quantum Software (10)
- RecA (1)
- scoring (1)
- selectivity (3)
- solvation energy (18)
- ss DNA (1)
- talk (5)
- toxicity (7)
- trombine (2)
- tuberculosis (3)
- Uncategorized (4)
- video (3)
- water (19)
Recent comments
- Talk@MIPT (in Russian) on Video recorded from "Water as a ferroelectric…" presentation at MIPT, November 5th, 2008
- FFT acceleration demonstration for (surface)GB methods on Water polarization charges in Generalized Born models.
- FFT acceleration demonstration for (surface)GB methods on O(N) Surface Charges Generalized Born calculation demonstration
- FFT acceleration demonstration for (surface)GB methods on O(N) SCGB solvation models: first “blood”
- FFT acceleration demonstration for (surface)GB methods on How to use Born surface charges to calculate solvation energy?
antiviral Archive
-
Drug resistance: evolution in action
Posted on January 6, 2010 | View CommentsIntroduction of drugs puts an evolutionary pressure on viruses and makes the viral proteins evolve. On the other hand, the change in the protein structure should be compatible with the protein function. The degree of the protein sequence conservativity is thus a measure of the... -
Quantum Pharmaceuticals collaborates with University of Pittsburgh on HIV drug discovery.
Posted on October 28, 2008 | View CommentsMoscow, October, 20 2008 Quantum Pharmaceuticals and University of Pittsburgh announced a drug discovery collaboration in HIV sphere. Under the terms of agreement Quantum Pharmaceuticals gets access to the target data from University of Pittsburgh. Quantum Pharmaceuticals will apply its industry leading computational technology to... -
Quantum Pharmaceuticals and Tibotec Pharmaceuticals enter antiviral drug discovery collabortaion.
Posted on May 24, 2008 | View CommentsQuantum Pharmaceuticals announces a drug discovery collaboration with Tibotec Pharmaceuticals (subsidiary of Johnson & Johnson). Under the terms of the agreement Quantum Pharmaceuticals will provide Tibotec Pharmaceuticals with the family of anti-viral drug hits. The drug hits were discovered by Quantum Pharmaceuticals using its proprietary... -
HIV-1 integrase drug discovery collaboration
Posted on October 28, 2006 | View CommentsMoscow, September, 28 2006 Quantum Pharmaceuticals and A.N. Belozersky Institute of Physico-Chemical Biology entered drug discovery collaboration aimed to discovery of novel small molecule inhibitors of HIV-1 integrase. HIV-1 integrase is one of the most promising targets in HIV drug discovery. Under the terms of...